Impaired efferocytosis by monocytes in multiple myeloma

Liang,Ying  Yu; Schwarzinger,Ilse; Simonitsch‑Klupp,Ingrid; Agis,Hermine; Oehler,Rudolf

doi:10.3892/ol.2018.8620

Impaired efferocytosis by monocytes in multiple myeloma

Authors:
- Ying Yu Liang
- Ilse Schwarzinger
- Ingrid Simonitsch‑Klupp
- Hermine Agis
- Rudolf Oehler
View Affiliations

Affiliations: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Laboratory Medicine, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Pathology, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, A‑1090 Vienna, Austria
Published online on: May 2, 2018 https://doi.org/10.3892/ol.2018.8620
Pages: 409-416

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Efficient clearance of apoptotic cells by efferocytosis is important for tissue homeostasis. Impaired efferocytosis leads to the accumulation of cell debris, which is regarded as a trigger in chronic inflammation and autoimmune diseases. Patients with hematological neoplastic disorders such as multiple myeloma (MM) exhibit high blood levels of apoptotic microparticles. The present study investigated whether these high levels of apoptotic microparticles are associated with insufficient dead cell clearance. Blood samples were collected from patients with MM immediately prior to and 3, 7 and 10 days after the initial cycle of bortezomib‑based therapy. In addition, bone marrow aspirates (BMA) were collected prior to and following therapy. Prior to therapy, a 52% reduction in efferocytosis by blood monocytes was observed compared with the healthy controls (P<0.017). This was associated with an elevated number of 7‑AAD+ dead cell remnants in the blood flow as well as in BMA. A portion of the blood samples contained active caspase 3. The subsequent bortezomib‑based therapy had no effect on efferocytosis, although the quantity of dead cell remnants decreased. This reduction was associated with a decline in cluster of differentiation 8 (CD8)+ and CD4+ T cells and an increase in the number of monocytes. However, of 28 distinct soluble immune‑modulating molecules (i.e. chemokines, cytokines and soluble co‑stimulators) only C‑C motif chemokine ligand 2 (CCL2), CCL24 and sCD27 were affected by bortezomib‑based therapy. The levels of all other molecules remained unchanged or were below the detection threshold in all samples. The present study results revealed that the presence of dead cell remnants in the blood and bone morrow of patients with MM is associated with impaired efferocytosis by monocytes; however, its contribution to inflammatory events during MM remains unclear.

View Figures

View References

1	Poon IKH, Lucas CD, Rossi AG and Ravichandran KS: Apoptotic cell clearance: Basic biology and therapeutic potential. Nat Rev Immunol. 14:166–180. 2014. View Article : Google Scholar : PubMed/NCBI
2	Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, Barcinski M, Brekken RA, Huang X, Hutchins JT, et al: Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 23:962–978. 2016. View Article : Google Scholar : PubMed/NCBI
3	Green DR, Oguin TH and Martinez J: The clearance of dying cells: Table for two. Cell Death Differ. 23:915–926. 2016. View Article : Google Scholar : PubMed/NCBI
4	Das A, Ganesh K, Khanna S, Sen CK and Roy S: Engulfment of apoptotic cells by macrophages: A role of microRNA-21 in the resolution of wound inflammation. J Immunol. 192:1120–1129. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ferracini M, Rios FJ, Pecenin M and Jancar S: Clearance of apoptotic cells by macrophages induces regulatory phenotype and involves stimulation of CD36 and platelet-activating factor receptor. Mediators Inflamm. 2013:9502732013. View Article : Google Scholar : PubMed/NCBI
6	Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, et al: Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest. 124:4737–4752. 2014. View Article : Google Scholar : PubMed/NCBI
7	Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al: Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI
8	Silva MT: Secondary necrosis: The natural outcome of the complete apoptotic program. FEBS Lett. 584:4491–4499. 2010. View Article : Google Scholar : PubMed/NCBI
9	Fernandez-Boyanapalli RF, Falcone EL, Zerbe CS, Marciano BE, Frasch SC, Henson PM, Holland SM and Bratton DL: Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment. J Allergy Clin Immunol. 136:1399–1401.e3. 2015. View Article : Google Scholar : PubMed/NCBI
10	Manoussakis MN, Fragoulis GE, Vakrakou AG and Moutsopoulos HM: Impaired clearance of early apoptotic cells mediated by inhibitory IgG antibodies in patients with primary Sjögren's syndrome. PLoS One. 9:e1121002014. View Article : Google Scholar : PubMed/NCBI
11	Hamon R, Homan CC, Tran HB, Mukaro VR, Lester SE, Roscioli E, Bosco MD, Murgia CM, Ackland ML, Jersmann HP, et al: Zinc and zinc transporters in macrophages and their roles in efferocytosis in COPD. PLoS One. 9:e1100562014. View Article : Google Scholar : PubMed/NCBI
12	Simpson JL, Gibson PG, Yang IA, Upham J, James A, Reynolds PN and Hodge S: AMAZES Study Research Group: Impaired macrophage phagocytosis in non-eosinophilic asthma. Clin Exp Allergy. 43:29–35. 2013. View Article : Google Scholar : PubMed/NCBI
13	Wickman G, Julian L and Olson MF: How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ. 19:735–742. 2012. View Article : Google Scholar : PubMed/NCBI
14	Aggarwal R, Ghobrial IM and Roodman GD: Chemokines in multiple myeloma. Exp Hematol. 34:1289–1295. 2006. View Article : Google Scholar : PubMed/NCBI
15	Caivano A, Laurenzana I, De Luca L, La Rocca F, Simeon V, Trino S, D'Auria F, Traficante A, Maietti M, Izzo T, et al: High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biol. 36:9739–9752. 2015. View Article : Google Scholar
16	Canella A, Harshman SW, Radomska HS, Freitas MA and Pichiorri F: The potential diagnostic power of extracellular vesicle analysis for multiple myeloma. Expert Rev Mol Diagn. 16:277–284. 2016. View Article : Google Scholar : PubMed/NCBI
17	Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, Dimopoulos M, et al: European perspective on multiple myeloma treatment strategies: Update following recent congresses. Oncologist. 17:592–606. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, et al: Current multiple myeloma treatment strategies with novel agents: A European perspective. Oncologist. 15:6–25. 2010. View Article : Google Scholar : PubMed/NCBI
19	Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR, Gleason C, Boise LH and Lonial S: Bortezomib-containing induction regimens in transplant-eligible myeloma patients: A meta-analysis of phase 3 randomized clinical trials. Cancer. 119:4119–4128. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ribatti D, Nico B and Vacca A: Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 25:4257–4266. 2006. View Article : Google Scholar : PubMed/NCBI
21	Straube C, Wehner R, Wendisch M, Bornhäuser M, Bachmann M, Rieber EP and Schmitz M: Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia. 21:1464–1471. 2007. View Article : Google Scholar : PubMed/NCBI
22	Arpinati M, Chirumbolo G, Nicolini B, Agostinelli C and Rondelli D: Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade). Bone Marrow Transplant. 43:253–259. 2009. View Article : Google Scholar : PubMed/NCBI
23	Liang YY, Arnold T, Michlmayr A, Rainprecht D, Perticevic B, Spittler A and Oehler R: Serum-dependent processing of late apoptotic cells for enhanced efferocytosis. Cell Death Dis. 5:e12642014. View Article : Google Scholar : PubMed/NCBI
24	Liang YY, Rainprecht D, Eichmair E, Messner B and Oehler R: Serum-dependent processing of late apoptotic cells and their immunogenicity. Apoptosis. 20:1444–1456. 2015. View Article : Google Scholar : PubMed/NCBI
25	Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T and Oehler R: Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest. 43:286–291. 2013. View Article : Google Scholar : PubMed/NCBI
26	Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, et al: Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med. 5:2350–2358. 2016. View Article : Google Scholar : PubMed/NCBI
27	Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, et al: Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 154:32–75. 2011. View Article : Google Scholar : PubMed/NCBI
28	Lamm W, Wohlfarth P, Bojic M, Schörgenhofer C, Drach J, Gisslinger H, Worel N, Schiefer A, Schulenburg A, Agis H, et al: Outcome in multiple myeloma patients eligible for stem cell transplantation: A Single-center experience. Oncology. 89:196–204. 2015. View Article : Google Scholar : PubMed/NCBI
29	Dehle FC, Mukaro VR, Jurisevic C, Moffat D, Ahern J, Hodge G, Jersmann H, Reynolds PN and Hodge S: Defective lung macrophage function in lung cancer ± chronic obstructive pulmonary disease (COPD/emphysema)-mediated by cancer cell production of PGE2? PLoS One. 8:e615732013. View Article : Google Scholar : PubMed/NCBI
30	McCubbrey AL and Curtis JL: Efferocytosis and lung disease. Chest. 143:1750–1757. 2013. View Article : Google Scholar : PubMed/NCBI
31	Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, et al: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 107:3575–3583. 2006. View Article : Google Scholar : PubMed/NCBI
32	Minarik J, Scudla V, Ordeltova M, Bacovsky J, Pika T and Langova K: Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. Eur J Haematol. 83:528–534. 2009. View Article : Google Scholar : PubMed/NCBI
33	Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P and Vandenabeele P: Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 12:860–875. 2012. View Article : Google Scholar : PubMed/NCBI
34	Fraser DA, Laust AK, Nelson EL and Tenner AJ: C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. J Immunol. 183:6175–6185. 2009. View Article : Google Scholar : PubMed/NCBI
35	Yadav A, Saini V and Arora S: MCP-1: Chemoattractant with a role beyond immunity: A review. Clin Chim Acta. 411:1570–1579. 2010. View Article : Google Scholar : PubMed/NCBI
36	Roca H, Varcos ZS, Sud S, Craig MJ and Pienta KJ: CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 284:34342–34354. 2009. View Article : Google Scholar : PubMed/NCBI
37	Kobayashi M, Jeschke MG, Shigematsu K, Asai A, Yoshida S, Herndon DN and Suzuki F: M2b monocytes predominated in peripheral blood of severely burned patients. J Immunol. 185:7174–7179. 2010. View Article : Google Scholar : PubMed/NCBI
38	Lens SM, Tesselaar K, van Oers MH and van Lier RA: Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol. 10:491–499. 1998. View Article : Google Scholar : PubMed/NCBI
39	Moon H, Na HY, Chong KH and Kim TJ: P2X7 receptor-dependent ATP-induced shedding of CD27 in mouse lymphocytes. Immunol Lett. 102:98–105. 2006. View Article : Google Scholar : PubMed/NCBI
40	Tagoug I, Plesa A and Dumontet C: Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol. 706:11–16. 2013. View Article : Google Scholar : PubMed/NCBI